KRYS Reports Preliminary Results for 2025, Outlines 2026 Objectives
KrystalKrystal(US:KRYS) ZACKS·2026-01-12 20:10

Key Takeaways KRYS expects Q4 Vyjuvek revenues of 106−106-107M on a preliminary basis, lifting full-year sales to 388−388-389M.KRYS benefited from strong U.S. uptake and expanded Vyjuvek approvals across Europe and Japan.KRYS expects key 2026 catalysts, including top-line data from KB801 and KB803 registrational studies.Krystal Biotech, Inc. (KRYS) expects preliminary unaudited net product revenues of 106−106-107 million from lead drug Vyjuvek in the fourth quarter of 2025, bringing full-year 2025 revenue forecas ...